Announcements Trials
Browse Landscape

Phase

Phase 2 147Phase 1 81Phase 3 57Phase 1/2 50Phase NA 33Phase EARLY_PHASE1 7Phase 4 7Phase 2/3 1

Status

Recruiting 3Not yet recruiting 2Terminated 1Completed 1

Sponsor Class

INDUSTRY 6OTHER 1

Study Type

Interventional 7

Sponsor

Cancer Type

Plasma cell 7Lymphoid 1

Conditions

Breast Neoplasms 27Neoplasms 10Carcinoma, Non-Small-Cell Lung 9Prostatic Neoplasms 7Multiple Myeloma 7Lung Neoplasms 7Melanoma 6Stomach Neoplasms 5Neoplasm Metastasis 4Leukemia, Myeloid, Acute 4Glioma 4Colorectal Neoplasms 4Carcinoma, Hepatocellular 4Tuberous Sclerosis 3Sarcoma 3Papillomavirus Infections 3Ovarian Neoplasms 3Hematologic Neoplasms 3Glioblastoma 3Warts 2Venous Thromboembolism 2Thyroid Neoplasms 2Skin Neoplasms 2Rectal Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Polycythemia Vera 2Oligodendroglioma 2Obesity 2Neoplasms by Site 2Myasthenia Gravis 2

Interventions

Lenalidomide 2Dexamethasone 2zanubrutinib 1tocilizumab 1talquetamab 1ixazomib 1ibrutinib 1carfilzomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 4 × Multiple Myeloma × 90 days × Clear all
NCT07609940 2026-05-27

POPLIN

Regeneron Pharmaceuticals

Phase 4 Not yet recruiting
30 enrolled
Plasma cell

Cytokine Release Syndrome, Multiple Myeloma

NCT06057402 2026-05-14

MagnetisMM15

Pfizer

Phase 4 Recruiting
80 enrolled
Plasma cell

Multiple Myeloma

NCT03934684 2026-05-11

Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma

Amgen

Phase 4 Completed
101 enrolled 14 charts
Plasma cell

Multiple Myeloma

NCT05201781 2026-05-08

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

Janssen Research & Development, LLC

Phase 4 Recruiting
295 enrolled
Plasma cell

Multiple Myeloma

NCT07030517 2026-05-08

A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma

Johnson & Johnson Private Limited

Phase 4 Recruiting
75 enrolled
Plasma cell

Multiple Myeloma

NCT03173092 2026-05-04

A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)

Takeda

Phase 4 Terminated
141 enrolled
Plasma cell

Multiple Myeloma

NCT07474961 2026-03-16

BLOOD-dose

Rigshospitalet, Denmark

Phase 4 Not yet recruiting
400 enrolled
LymphoidPlasma cell

Waldenstrom Macroglobulinemia, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡